ArticleMicrobial biotechnology2025
Development of a Ready-To-Use Bioluminescence Immunosensor for the One-Step Sensitive Detection of Antibodies Against African Swine Fever Virus.
Article in Microbial biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A broadly applicable split-luciferase biosensor approach for rapid antibody detection in emerging infectious diseases.Applied microbiology and biotechnology · 2026Article
- Development of a Ready-To-Use Bioluminescence Immunosensor for the One-Step Sensitive Detection of Antibodies Against African Swine Fever Virus.Microbial biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Rapid and reliable analytical techniques play important roles in various research fields and are particularly crucial for diagnosing infectious diseases in clinical settings. African swine fever (ASF) is a devastating viral pig disease for which no effective vaccine is available. The ongoing ASF pandemic has highlighted the importance of rapid and accurate diagnosis, which enables the timely implementation of control and eradication measures. In this study, a ready-to-use bioluminescence immunosensor based on a split-nanoluciferase (NanoLuc) reporter system was proposed for the one-step sensitive detection of ASF virus (ASFV) antibodies. Specifically, the NanoLuc subunits SmBiT/LgBiT were each genetically fused to the ASFV p30 protein and protein G and used as probes. The simultaneous binding of the probes to ASFV IgGs induced the reconstitution of functional NanoLuc, which can generate a strong bioluminescent signal output by catalysing the substrate furimazine. This immunosensor allows the rapid and homogeneous detection of ASFV antibodies in solution, requiring only one incubation step of 10 min. This immunosensor also has high sensitivity, high specificity, and a wide dynamic range and is particularly promising for point-of-care testing. Comparative analysis of clinical samples validated the reliability and robustness of this approach and demonstrated high consistency with enzyme-linked immunosorbent assay (ELISA) results (concordance rate: 98.71%). These results suggest that the proposed immunosensor provides an attractive alternative to conventional immunoassays and could be easily repurposed by generating specific probes for antibody detection in other diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.